Mark Sheehan

ORCID: 0009-0007-4916-796X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer-related molecular mechanisms research
  • Molecular Biology Techniques and Applications
  • Virus-based gene therapy research
  • Environmental DNA in Biodiversity Studies
  • RNA and protein synthesis mechanisms
  • Viral Infectious Diseases and Gene Expression in Insects
  • RNA modifications and cancer
  • Single-cell and spatial transcriptomics
  • Viral gastroenteritis research and epidemiology
  • CAR-T cell therapy research
  • Tryptophan and brain disorders
  • Diet and metabolism studies
  • Neuroscience and Neuropharmacology Research
  • Viral Infections and Immunology Research
  • Extracellular vesicles in disease
  • CRISPR and Genetic Engineering
  • Cell Image Analysis Techniques
  • Gene Regulatory Network Analysis
  • RNA Interference and Gene Delivery
  • Cancer Genomics and Diagnostics
  • Schizophrenia research and treatment
  • Cannabis and Cannabinoid Research
  • Stress Responses and Cortisol

Pfizer (United States)
2017-2025

Biogen (United States)
2019-2023

Abstract Psychiatric disorders such as schizophrenia (SCZ), bipolar disorder (BD), and major depressive (MDD) arise from complex interactions between genetic environmental factors. Common variants associated with multiple psychiatric suggest that shared architecture could contribute to divergent clinical syndromes. To evaluate transcriptional alterations across connected brain regions, Affymetrix microarrays were used profile postmortem dorsolateral prefrontal cortex (DLPFC), hippocampus,...

10.1038/s41398-019-0492-8 article EN cc-by Translational Psychiatry 2019-05-23

Many current gene therapy targets use recombinant adeno-associated virus (AAV). The majority of delivered AAV therapeutics persist as episomes, separate from host DNA, yet some viral DNA can integrate into in different proportions and at genomic locations. potential for integration leading to oncogenic transformation has led regulatory agencies require investigation events following preclinical species. In the present study, tissues were collected cynomolgus monkeys mice 6 8 weeks,...

10.1016/j.omtm.2023.04.009 article EN cc-by-nc-nd Molecular Therapy — Methods & Clinical Development 2023-05-04

The cuprizone (CPZ) model is widely used for modeling demyelination in multiple sclerosis (MS) and testing potential remyelination therapies. We integrated single-cell spatial transcriptomics (ST) to fine map the cellular molecular responses during de remyelination. ST revealed global neuroinflammation brain beyond corpus callosum, with region-specific differences. identified oligodendroglia microglia as two major cell types significant transcriptomic changes model. Ligand‒receptor pairing...

10.1101/2025.02.07.637125 preprint EN cc-by bioRxiv (Cold Spring Harbor Laboratory) 2025-02-08

Status epilepticus (SE) is a life-threatening and commonly drug-refractory condition. Novel therapies are needed to rapidly terminate seizures prevent mortality morbidity. Monoacylglycerol lipase (MAGL) the key enzyme responsible for hydrolysis of endocannabinoid 2-arachidonoylglycerol (2-AG) major contributor brain pool arachidonic acid (AA). Inhibiting monoacylglycerol modulates synaptic activity neuroinflammation, 2 mediators excessive neuronal activation underlying seizures. We studied...

10.1111/epi.13950 article EN Epilepsia 2017-11-24

Abstract Background Single-cell RNA sequencing is a state-of-the-art technology to understand gene expression in complex tissues. With the growing amount of data being generated, standardization and automation analysis are critical generating hypotheses discovering biological insights. Results Here, we present scRNASequest, semi-automated single-cell RNA-seq (scRNA-seq) workflow which allows (1) preprocessing from raw UMI count data, (2) harmonization by one or multiple methods, (3)...

10.1186/s12864-023-09332-2 article EN cc-by BMC Genomics 2023-05-02

RNA medicines have become a promising platform for therapeutic use in recent years. Understanding the immunomodulatory effects of novel mRNA-LNPs is crucial future development. An vitro whole blood assay was developed to assess impact on immune cell function, cytokine release, and complement activation. significantly increased CD69 expression T cells natural killer (NK) cells, CD80/CD86 myeloid subsets, dose-dependent fashion. Furthermore, elicited robust release pro-inflammatory cytokines,...

10.1016/j.ymthe.2024.12.019 article EN cc-by-nc-nd Molecular Therapy 2024-12-01
Coming Soon ...